Isabelle Lousada

1.5k total citations · 1 hit paper
25 papers, 864 citations indexed

About

Isabelle Lousada is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Isabelle Lousada has authored 25 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Nephrology and 5 papers in Genetics. Recurrent topics in Isabelle Lousada's work include Amyloidosis: Diagnosis, Treatment, Outcomes (24 papers), Parathyroid Disorders and Treatments (15 papers) and Dermatological and Skeletal Disorders (5 papers). Isabelle Lousada is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (24 papers), Parathyroid Disorders and Treatments (15 papers) and Dermatological and Skeletal Disorders (5 papers). Isabelle Lousada collaborates with scholars based in United States, United Kingdom and Italy. Isabelle Lousada's co-authors include Giampaolo Merlini, Spencer Guthrie, Raymond L. Comenzo, Heather Landau, Martha Grogan, Sharmila Dorbala, Mathew S. Maurer, Thibaud Damy, Brian Drachman and Yukio Ando and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Leukemia.

In The Last Decade

Isabelle Lousada

20 papers receiving 853 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis

2019 331 citations Mathew S. Maurer, Sharmila Dorbala et al. profile →

Peers

Countries citing papers authored by Isabelle Lousada

Since Specialization

Citations

This map shows the geographic impact of Isabelle Lousada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Lousada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Lousada more than expected).

Fields of papers citing papers by Isabelle Lousada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Lousada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Lousada. The network helps show where Isabelle Lousada may publish in the future.

Co-authorship network of co-authors of Isabelle Lousada

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Lousada. A scholar is included among the top collaborators of Isabelle Lousada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Lousada. Isabelle Lousada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey 2025 ·Amyloid ·Sabrina Rebello, (unknown), José Nativi-Nicolau, Chafic Karam, Martha Grogan, Isabelle Lousada, Matthew J. Maurer	0
2	Reliability and validity of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire impact scales 2025 ·Journal of Patient-Reported Outcomes ·(unknown), (unknown), (unknown), Isabelle Lousada, Kristen McCausland, Michelle K. White, Sabrina Rebello, Jakob Bue Bjørner	0
3	Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review 2025 ·Journal of the American Heart Association ·Martha Grogan, Francisco López-Jiménez, Spencer Guthrie, (unknown), R.Eugene Langevin, Isabelle Lousada, Ronald Witteles, Ajay K. Royyuru, Michael Rosenzweig, Sarah Cairns‐Smith, David Ouyang	3
4	Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis 2024 ·Therapeutic Innovation & Regulatory Science ·James Signorovitch, Jialü Zhang, David T. Brown, Preston Dunnmon, Liang Xiu, Nicolae Done, (unknown), Yolanda Barbáchano, Isabelle Lousada	1
5	Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis 2024 ·Kidney International Reports ·Nelson Leung, Raymond L. Comenzo, Julian D. Gillmore, Andrea Havasi, Efstathios Kastritis, Spencer Guthrie, James Signorovitch, (unknown), Isabelle Lousada, Yolanda Barbáchano, Krishna Prasad, Kimberly A. Smith	2
6	Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group 2023 ·Patient Related Outcome Measures ·Avery A. Rizio, Michelle K. White, Anita D’Souza, (unknown), (unknown), Tiffany P. Quock, James Signorovitch, Isabelle Lousada, Vaishali Sanchorawala	10
7	The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure 2023 ·Patient Related Outcome Measures ·Meaghan O’Connor, (unknown), Lynne Broderick, Kristen McCausland, (unknown), Sabrina Rebello, (unknown), Isabelle Lousada	2
8	Treatment Patterns and Outcomes for Patients with Light Chain (AL) Amyloidosis: Analysis of a Large US Claims Database 2023 ·Blood ·Genevieve Lyons, Jeffrey C. Thompson, Isabelle Lousada, Matthew J. Maurer, (unknown), (unknown)	0
9	FINANCIAL TOXICITY AND PATIENT-REPORTED ECONOMIC BURDEN IN PATIENTS WITH ATTR: RESULTS FROM AMYLOIDOSIS RESEARCH CONSORTIUM’S ATTR TREATMENT AFFORDABILITY PATIENT AND CAREGIVER SURVEY 2022 ·Journal of the American College of Cardiology ·Sabrina Rebello, (unknown), José Nativi-Nicolau, Chafic Karam, Martha Grogan, Isabelle Lousada, Mathew S. Maurer	2
10	Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database 2022 ·Blood ·(unknown), Quan V. Doan, Jennifer Evans, (unknown), Thomas Defay, Guillermo del Angel, (unknown), Candida Cristina Quarta, Matthew J. Maurer, Isabelle Lousada	0
11	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types 2020 ·Blood Reviews ·Cindy Varga, Sharmila Dorbala, Isabelle Lousada, Michael Polydefkis, Ashutosh Wechalekar, Matthew J. Maurer, Raymond L. Comenzo	18
12	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy 2020 ·Journal of Neurology ·David Adams, Yukio Ando, João Melo Beirão, Teresa Coelho, Morie A. Gertz, Julian D. Gillmore, Philip N. Hawkins, Isabelle Lousada, Ole B. Suhr, Giampaolo Merlini	157
13	The Impact of AL Amyloidosis 2020 ·Hematology/Oncology Clinics of North America ·Isabelle Lousada, (unknown)	2
14	Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments 2020 ·Blood ·Isabelle Lousada, (unknown), (unknown), (unknown), Lisa Mendelson, Vaishali Sanchorawala	0
15	Cardiac Amyloidosis: Current Insights from Patients and Cardiologists Journeying Together 2019 ·Journal of Cardiac Failure ·Adam Castaño, Marianna Bruno, Isabelle Lousada, (unknown), (unknown), Younos Abdulsattar, José Nativi-Nicolau	1
16	AMYLOIDOSIS RESEARCH CONSORTIUM CARDIAC AMYLOIDOSIS SURVEY: RESULTS FROM PATIENTS WITH AL AND ATTR AMYLOIDOSIS AND THEIR CAREGIVERS 2018 ·Journal of the American College of Cardiology ·Isabelle Lousada, Matthew J. Maurer, (unknown), Spencer Guthrie, (unknown), Martha Grogan	4
17	Light Chain (AL) Amyloidosis: The Journey to Diagnosis 2017 ·Patient ·Kristen McCausland, Michelle K. White, Spencer Guthrie, Tiffany P. Quock, (unknown), Isabelle Lousada, Martha Bayliss	76
18	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis 2016 ·Leukemia ·Giampaolo Merlini, Isabelle Lousada, Yukio Ando, Angela Dispenzieri, Morie A. Gertz, Martha Grogan, Matthew J. Maurer, Vaishali Sanchorawala, Ashutosh Wechalekar, Giovanni Palladini, Ray Comenzo	66
19	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium 2015 ·Advances in Therapy ·Isabelle Lousada, Raymond L. Comenzo, Heather Landau, Spencer Guthrie, Giampaolo Merlini	157
20	Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium 2015 ·Orphanet Journal of Rare Diseases ·Isabelle Lousada, Raymond L. Comenzo, Heather Landau, Spencer Guthrie, Giampaolo Merlini	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact